Close Menu

NEW YORK (GenomeWeb) – Flagship Biosciences today said it is collaborating with Advanced Cell Diagnostics for the use of its RNAscope technology. 

Flagship said it is using ACD's technology to support ongoing CLIA-based clinical trials of its clients. Steve Potts, vice president of sales and marketing for Westminster, Colo.-based Flagship, told GenomeWeb in an email that his firm is using RNAscope and customizing and optimizing the technology for use in trials with "several large" undisclosed pharmaceutical clients. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.